Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 6/20 | 0.59 |
| ▸ | HPGDS | O60760 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495498 | 0.91 | GABRA5 (0.52) | GABRA5HPGDSCYP2C9MAPK14MAPK11 | |
| SCHEMBL1543132 | 0.91 | GABRA5 (0.56) | GABRA5HPGDSCYP2C9MAPK14MAPK11 | |
| SCHEMBL16495495 | 0.91 | GABRA5 (0.52) | GABRA5HPGDSCYP2C9MAPK14MAPK11 | |
| SCHEMBL16496176 | 0.91 | MAP4K4 (0.58) | GABRA5HPGDSCYP2C9MAPK14MAPK11 | |
| SCHEMBL16496399 | 0.89 | HPGDS (0.55) | GABRA5HPGDSCYP2C9MAPK14MAPK11 | |
| SCHEMBL16496065 | 0.88 | HPGDS (0.54) | GABRA5HPGDSCYP2C9MAPK14MAPK11 | |
| SCHEMBL16495594 | 0.87 | GABRA5 (0.53) | GABRA5HPGDSCYP2C9 | |
| SCHEMBL16495629 | 0.86 | HPGDS (0.56) | GABRA5HPGDSMAP4K4 | |
| SCHEMBL14802423 | 0.85 | HPGDS (0.51) | GABRA5HPGDSCYP2C9MAPK14MAPK11 | |
| SCHEMBL246322 | 0.85 | HPGDS (0.51) | GABRA5HPGDSCYP2C9MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| EP-2307378-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009153721-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153721-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | GABRA5 1938/4885HPGDS 1073/4885CYP2C9 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.